ArticleOncology and therapy2026

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy.

Jorge J Nieva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.